538 studies on GIP agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Understanding the precise mechanisms by which Tirzepatide impacts pancreatic alpha and beta cell function and insulin sensitivity is critically important. This mechanistic insight can refine our understanding of optim…
The withdrawal of this study means a potential avenue for exploring enhanced weight loss and metabolic improvements, particularly through muscle preservation with Bimagrumab alongside Tirzepatide's established effects…
Persistent obesity after bariatric surgery represents a significant clinical challenge, often leading to comorbidities and reduced quality of life. If Tirzepatide proves effective and safe in this specific patient pop…
This foundational Phase 1 study is crucial for the development of tirzepatide, providing essential data on its pharmacokinetics and safety in humans. Understanding how the drug is absorbed, distributed, metabolized, a…
This pilot study is critically important as it addresses a significant unmet medical need for safe and effective weight management in obese kidney transplant recipients. Successful outcomes could establish Tirzepatide…
Understanding the extrapancreatic effects of GIP and GLP-1 is crucial for optimizing current and developing future treatments for type 2 diabetes and obesity. This research will provide critical insights into why comb…
This study is incredibly significant because it seeks to confirm if tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for weight management, can directly improve long-term health outcomes beyond just…
This research is crucial because it addresses a significant unmet need for effective treatments targeting adiposopathy in a vulnerable population with CKD and Type 2 Diabetes. Understanding how GLP-1RAs impact fat dis…
This research is critical for advancing the use of real-world evidence (RWE) in medical decision-making and drug development. If the emulation successfully replicates the SUMMIT trial's findings, it would validate the…
The potential for tirzepatide, a dual GLP-1 and GIP receptor agonist, to address both obesity and methamphetamine use disorder simultaneously represents a significant advancement in addiction medicine and metabolic he…
If these anticipated findings are confirmed, this study could redefine the therapeutic approach to obesity and its metabolic complications, moving beyond mere weight loss to direct reversal of underlying metabolic dys…
Obtaining real-world data on Tirzepatide is paramount for understanding its performance and tolerability outside the highly controlled environment of earlier clinical trials. This study will provide invaluable insight…
The potential to preserve lean mass during GLP-1 induced weight loss is crucial for improving long-term health outcomes and metabolic function in individuals with obesity. Preventing muscle loss can enhance strength, …
If successful, this pilot study could reveal a novel therapeutic application for tirzepatide, potentially offering significant relief for post-menopausal women with obesity suffering from vasomotor symptoms. Beyond sy…
As this is a recruiting clinical trial, specific results are not yet available; however, the study aims to demonstrate significant improvements in key health metrics. Researchers hypothesize that preoperative tirzepat…
This study highlights Tirzepatide's potential as a powerful tool for long-term weight management, particularly for individuals who have already achieved initial success with lifestyle interventions. The ability to not…
The successful integration of tirzepatide with automated insulin delivery could represent a paradigm shift in Type 1 Diabetes management, offering a novel strategy to improve glucose control beyond current capabilitie…
The provided research record is a study protocol description from ClinicalTrials.gov and, as such, does not contain specific efficacy or safety results from the trial. The study, NCT06445075, is listed as COMPLETED, i…
The study aimed to demonstrate that tirzepatide significantly impacts food intake and modulates brain activity in areas associated with appetite and reward. While specific quantitative results are not detailed in this…
This planned study is significant because it aims to explore a novel therapeutic avenue for a highly complex patient population: individuals with obesity and chronic kidney failure. If Tirzepatide demonstrates a favor…
If successful, this study could represent a significant advancement in the treatment of adolescent obesity and its associated health burdens. The potential for tirzepatide to not only reduce weight but also improve ca…
Successfully demonstrating the feasibility and efficacy of tirzepatide for weight loss in early-stage HR+/Her2- breast cancer patients could represent a significant advancement in supportive cancer care. Effective wei…
This Phase 3 trial is highly significant as it directly compares Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, against a standard rapid-acting insulin, insulin lispro (U100), in a challenging patient populatio…
This study is critically important as it will provide a head-to-head comparison of the most effective current treatments for obesity, offering invaluable data for clinical decision-making. If Semaglutide or Tirzepatid…
The findings of this study are crucial for enhancing patient safety during surgical procedures for individuals on GLP-1/GIP agonists. If standard fasting guidelines prove insufficient, it could lead to revised pre-ope…
The potential for tirzepatide, a drug primarily known for its efficacy in type 2 diabetes and weight management, to treat Hidradenitis Suppurativa is highly significant. If successful, this study could repurpose an ex…
This pilot trial is crucial as it explores a novel therapeutic avenue for Alcohol Use Disorder (AUD), a condition with significant unmet medical needs. If tirzepatide, a GLP-1/GIP receptor agonist primarily used for d…
The bold challenge of weight regain after successful initial weight loss significantly impacts long-term health outcomes for individuals with obesity. If Retatrutide proves effective in maintaining weight reduction, i…
This trial is crucial because retatrutide, a novel triple agonist targeting GIP, GLP-1, and glucagon receptors, holds significant promise for treating obesity and its complex comorbidities. If successful, it could off…
Ensuring bioequivalence and safety across different drug delivery devices is a critical step in pharmaceutical development and patient access. If the Test Device proves to be bioequivalent and equally safe, it could f…
The initiation of this large-scale clinical trial for Retatrutide is a pivotal step towards addressing the interconnected epidemics of Type 2 Diabetes and obesity with a single, highly potent therapeutic agent. If suc…
If successful, this trial could represent a significant advancement for patients with Type 2 Diabetes and renal impairment, a group with limited treatment options and high unmet medical need. Retatrutide could offer a…
The findings from this trial are highly anticipated, as obesity is a major driver of osteoarthritis progression and a significant barrier to effective management. Retatrutide's ability to induce substantial weight los…
The successful modulation of calorie intake and energy expenditure by LY3437943 could represent a significant advancement in obesity treatment. If LY3437943 demonstrates a favorable impact on these parameters, it coul…
If successful, this study could demonstrate a significant cardio-renal protective effect of Retatrutide beyond its known weight-loss benefits. This would be a crucial advancement, as current treatments for obesity oft…
The SYNERGY-OUTCOMES study holds immense significance as it addresses a critical unmet medical need for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition without approved pharmacologic trea…
If successful, this Phase 2 study could demonstrate that LY3437943 is a highly effective and well-tolerated treatment for obesity and overweight with comorbidities, potentially offering a new therapeutic avenue. The e…